DK4426270T3 - Lipid nanopartikler til forsyning af oligonucleotider - Google Patents
Lipid nanopartikler til forsyning af oligonucleotiderInfo
- Publication number
- DK4426270T3 DK4426270T3 DK22813505.9T DK22813505T DK4426270T3 DK 4426270 T3 DK4426270 T3 DK 4426270T3 DK 22813505 T DK22813505 T DK 22813505T DK 4426270 T3 DK4426270 T3 DK 4426270T3
- Authority
- DK
- Denmark
- Prior art keywords
- oligonucleotides
- delivery
- lipid nanoparticles
- nanoparticles
- lipid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205904 | 2021-11-02 | ||
| EP22179399 | 2022-06-16 | ||
| PCT/EP2022/080581 WO2023078950A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4426270T3 true DK4426270T3 (da) | 2025-09-22 |
Family
ID=84364268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22813505.9T DK4426270T3 (da) | 2021-11-02 | 2022-11-02 | Lipid nanopartikler til forsyning af oligonucleotider |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236599A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4426270B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540108A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099377A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381463A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236653A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4426270T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3042660T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4426270T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312432B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005109A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4426270T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023078950A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202403360B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| JP2025538515A (ja) * | 2022-11-25 | 2025-11-28 | 艾斯拓康医薬科技(北京)有限公司 | イオン化脂質及びその応用 |
| JP2025534494A (ja) * | 2022-12-23 | 2025-10-15 | グリーン・クロス・コーポレイション | イオン化可能な脂質及びその使用 |
| CN119219539A (zh) * | 2023-06-29 | 2024-12-31 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| AU2024381228A1 (en) | 2023-11-13 | 2026-05-28 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025128696A1 (en) * | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
| WO2026112559A1 (en) * | 2024-11-25 | 2026-05-28 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026117525A1 (en) * | 2024-11-26 | 2026-06-04 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| EP3638678B1 (en) * | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 MX MX2024005109A patent/MX2024005109A/es unknown
- 2022-11-02 AU AU2022381463A patent/AU2022381463A1/en active Pending
- 2022-11-02 WO PCT/EP2022/080581 patent/WO2023078950A1/en not_active Ceased
- 2022-11-02 ES ES22813505T patent/ES3042660T3/es active Active
- 2022-11-02 CA CA3236653A patent/CA3236653A1/en active Pending
- 2022-11-02 JP JP2024525411A patent/JP2024540108A/ja active Pending
- 2022-11-02 KR KR1020247018058A patent/KR20240099377A/ko active Pending
- 2022-11-02 PL PL22813505.9T patent/PL4426270T3/pl unknown
- 2022-11-02 EP EP22813505.9A patent/EP4426270B1/en active Active
- 2022-11-02 IL IL312432A patent/IL312432B2/en unknown
- 2022-11-02 EP EP25189933.2A patent/EP4613741A3/en not_active Withdrawn
- 2022-11-02 FI FIEP22813505.9T patent/FI4426270T3/fi active
- 2022-11-02 US US18/705,479 patent/US20250236599A1/en active Pending
- 2022-11-02 DK DK22813505.9T patent/DK4426270T3/da active
-
2024
- 2024-04-30 ZA ZA2024/03360A patent/ZA202403360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312432B1 (en) | 2026-01-01 |
| PL4426270T3 (pl) | 2025-11-24 |
| EP4426270B1 (en) | 2025-07-23 |
| IL312432B2 (en) | 2026-05-01 |
| EP4613741A2 (en) | 2025-09-10 |
| WO2023078950A1 (en) | 2023-05-11 |
| EP4613741A3 (en) | 2025-11-12 |
| CA3236653A1 (en) | 2023-05-11 |
| ZA202403360B (en) | 2025-08-27 |
| US20250236599A1 (en) | 2025-07-24 |
| JP2024540108A (ja) | 2024-10-31 |
| IL312432A (en) | 2024-06-01 |
| ES3042660T3 (en) | 2025-11-24 |
| KR20240099377A (ko) | 2024-06-28 |
| MX2024005109A (es) | 2024-05-31 |
| EP4426270A1 (en) | 2024-09-11 |
| FI4426270T3 (fi) | 2025-09-12 |
| AU2022381463A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4013385T3 (da) | Forbedrede lipidnanopartikler til indgivelse af nukleinsyrer | |
| DK3908568T3 (da) | Lipider til lipidnanopartikellevering af aktivstoffer | |
| IL309505A (en) | Lipid nanoparticles for nucleic acid delivery | |
| DK4426269T3 (da) | Lipid nanopartikler til indgift af oligonucleotid | |
| IL282995A (en) | Lipid nanoparticle formulations | |
| IL283545A (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| DK3860561T3 (da) | Bionedbrydelige lipider til levering af aktive stoffer | |
| IL266501A (en) | An improved ice-based lipid nanoparticle formulation for mRNA delivery | |
| DK2539451T3 (da) | Sammensætninger til målrettet tilførsel af siRNA | |
| DK3310904T3 (da) | System til cellulær indgivelse af målrettet aktivstof | |
| EP3558942C0 (en) | IONIZABLE CATIONIC LIPID FOR RNA ABSORPTION | |
| BR112014030714A2 (pt) | composto de lipídeo ionizável , composições , carreador de fármaco , formulação farmacêutica e método de entrega de um fármaco | |
| DK3221293T3 (da) | Ioniserbar kationisk lipid til RNA-afgivelse | |
| DK3357491T3 (da) | Farmaceutisk sammensætning til afgivelse af et anionisk medikament | |
| SMT201600099B (it) | Derivati citotossici di benzodiazepine | |
| DK2611467T3 (da) | Små liposomer til afgivelse af immunogen-kodende RNA | |
| PL3191502T3 (pl) | Ukierunkowane dostarczanie substancji leczniczych zawierających aminę trzeciorzędową | |
| EP4277603A4 (en) | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF mRNA | |
| DK3378482T3 (da) | Formulering til administration af antitumorlægemiddel | |
| DK3049117T3 (da) | Ultralydsmedieret afgivelse af lægemidler | |
| DK3331495T3 (da) | Flydende polymerleveringssystem til forlænget indgivelse af lægemidler | |
| EP3344232A4 (en) | MICELLES FOR MUCOADHESIVE ACTIVE INFUSION | |
| DK3325081T3 (da) | Fremgangsmåder til lymfatisk levering af aktive stoffer | |
| EP4458843A4 (en) | MRNA VACCINE | |
| EP4408425A4 (en) | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY |